Maridebart cafraglutide · source year
14 selected, source-linked Maridebart cafraglutide records carrying a 2026 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
14 selected records.
2 represented types.
14 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07575399 at 2026-09-09T19:17:17.083Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41337722 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41337723 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗